Position in TNGX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$41,217,904
New position
Shares Held
1,318,551
first reported quarter
Ownership
0.782%
of shares outstanding
% of Portfolio
9.95%
of 13F equity value
Holder Rank
#34
of 247 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026DV EQUITIES, LLC holds $112,761,771 across 19 Biotechnology names. TNGX ranks #1 (36.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TNGX |
Tango Therapeutics, Inc.
This page
|
1,318,551 | $41,217,904 | |
| 2 | PHVS |
Pharvaris N.V.
|
482,524 | $16,685,679 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
47,666 | $8,926,888 | |
| 4 | MANE |
Veradermics, Inc
|
70,000 | $8,605,800 | |
| 5 | ASMB |
Assembly Biosciences, Inc.
|
226,415 | $6,221,884 | |
| 6 | AVTX |
Avalo Therapeutics, Inc.
|
332,213 | $6,139,296 | |
| 7 | NERV |
Minerva Neurosciences, Inc.
|
754,397 | $4,186,903 | |
| 8 | ELVN |
Enliven Therapeutics, Inc.
|
76,250 | $3,869,687 |
All Filings in TNGX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $41,217,904 | 1,318,551 | Shares | Other | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||